All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

doxecitine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	5786	951-77-9

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: doxecitine deoxycytidine

Doxecitine is approved in combination with doxribtimine under the name KYGEVVI. The primary mechanism of action of doxecitine and doxribtimine is the incorporation of nucleosides deoxycytidine (dC) and deoxythymidine (dT) into skeletal muscle mitochondrial deoxyribonucleic acid (DNA) to restore mitochondrial DNA copy number and improve skeletal muscle function in patients with TK2d. Doxecitine and doxribtimine likely utilize residual TK2 activity as well as cytosolic phosphorylation pathways such as thymidine kinase 1 and deoxycytidine kinase to increase mitochondrial DNA precursors deoxycytidine triphosphate and deoxythymidine triphosphate in the mitochondria. Molecular weight: 227.22 Formula: C9H13N3O4 CLOGP: -1.53 LIPINSKI: 0 HAC: 7 HDO: 3 TPSA: 108.38 ALOGS: ROTB: 2 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
March 26, 2026	EMA	UCB Pharma
Nov. 11, 2025	FDA	UCB Inc

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A16AX29	ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Various alimentary tract and metabolism products

Related Drugs by ATC class:

A16AX Various alimentary tract and metabolism products 23 drugs

anethole trithionedoxribtimineeliglustatfosdenopteringivosiranglycerol phenylbutyratelonafarniblumasiranmigalastatmiglustatnedosirannitisinone show all 23 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Thymidine kinase 2 deficiency	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
2GM/PACKET;2GM/PACKET	KYGEVVI	UCB INC	N219792	Nov. 3, 2025	RX	FOR SOLUTION	ORAL	10471087	Aug. 7, 2036	TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS
2GM/PACKET;2GM/PACKET	KYGEVVI	UCB INC	N219792	Nov. 3, 2025	RX	FOR SOLUTION	ORAL	11649259	Aug. 19, 2040	TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
2GM/PACKET;2GM/PACKET	KYGEVVI	UCB INC	N219792	Nov. 3, 2025	RX	FOR SOLUTION	ORAL	Nov. 3, 2030	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Reverse transcriptase/RNaseH	Enzyme		Q72547_9HIV1		Kd	5.96		CHEMBL

External reference:

ID	Source
DCZ	PDB_CHEM_ID
CHEMBL66115	ChEMBL_ID
C000732038	MESH_SUPPLEMENTAL_RECORD_UI
C0011485	UMLSCUI
CHEBI:15698	CHEBI
DB02594	DRUGBANK_ID
11755	INN_ID
D12465	KEGG_DRUG
13711	PUBCHEM_CID
44509	MMSL
d10335	MMSL
020283	NDDF
0W860991D6	UNII
2642208	RXNORM
D003841	MESH_DESCRIPTOR_UI
0W860991D6	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
KYGEVVI	HUMAN PRESCRIPTION DRUG LABEL	2	50474-350	POWDER, FOR SOLUTION	2 g	ORAL	NDA	28 sections